Anti-Inflammatory Therapeutics Market by Indication (Arthritis, Respiratory diseases, Multiple sclerosis, Psoriasis, Inflammatory bowel disease) and Drug Class (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs), Corticosteroids) - Global Opportunity Analysis and Industry Forecast, 2014 - 2020
Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD). According to World Health Organization (WHO), approximately 235 million people suffer from asthma in the world. Symptomatic relief during the inflammation provides relief to the patients suffering from inflammatory autoimmune diseases. Although there are multiple anti-inflammatory drugs approved in the market, there is an indispensable need for better and novel anti-inflammatory therapeutics with lesser side effects and better efficacy.
The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth.
The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period.
Geographically, the market is segmented into four regions namely North America, Europe, Asia-Pacific and LAMEA. Among regions, North America holds the largest share accounting for 45.7% share of the global anti-inflammatory therapeutics market; however, the Asia-Pacific region is expected to exhibit the fastest growth during the forecast period. Major market players have adopted innovative strategies such novel drug development and product launch (novel and indication expansion) to increase their market presence. In 2014, AstraZeneca had five anti-inflammatory drugs in the final stages of drug development. These drugs are lesinurad, sifalimumab, anifrolumab, mavrilimumab and brodalumab. The companies have filed new patents to overcome the issues of patent expiries of their existing drugs, and to gain a prominent market share. The key companies profiled in this report include Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, and Amgen.
KEY MARKET BENEFITS:
The Global Anti-inflammatory Therapeutics Market is segmented below:
The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth.
The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period.
Geographically, the market is segmented into four regions namely North America, Europe, Asia-Pacific and LAMEA. Among regions, North America holds the largest share accounting for 45.7% share of the global anti-inflammatory therapeutics market; however, the Asia-Pacific region is expected to exhibit the fastest growth during the forecast period. Major market players have adopted innovative strategies such novel drug development and product launch (novel and indication expansion) to increase their market presence. In 2014, AstraZeneca had five anti-inflammatory drugs in the final stages of drug development. These drugs are lesinurad, sifalimumab, anifrolumab, mavrilimumab and brodalumab. The companies have filed new patents to overcome the issues of patent expiries of their existing drugs, and to gain a prominent market share. The key companies profiled in this report include Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc., Novartis, F. Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, and Amgen.
KEY MARKET BENEFITS:
- The report provides a quantitative analysis of the current market and estimations during 2014 - 2020 that assist in identifying the prevailing market opportunities to capitalize.
- Exhaustive analysis of the global anti-inflammatory therapeutics market by product type helps in understanding the types of therapeutics that are currently being used along with the categories that would gain prominence in the future.
- Competitive intelligence (of leading manufacturers and distributors of anti-inflammatory therapeutics) helps in understanding the competitive scenario across the geographies.
- Comprehensive analysis of factors that drive and restrict the growth of the global anti-inflammatory therapeutics market is provided.
- SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.
- The Country level analysis of anti-inflammatory therapeutics market conditions has been provided in this report.
The Global Anti-inflammatory Therapeutics Market is segmented below:
- Global Anti-inflammatory Therapeutics Market By Indication
- Arthritis
- Respiratory diseases
- Multiple sclerosis
- Psoriasis
- Inflammatory bowel disease
- Other inflammatory diseases
- Global Anti-inflammatory Therapeutics Market Drug Class
- Anti-inflammatory Biologics
- Non-Steroidal Anti-inflammatory drugs (NSAIDs)
- Corticosteroids
- Global Anti-inflammatory Therapeutics Market By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- Germany
- France
- Others
- Asia-Pacific
- China
- Japan
- India
- Others
- LAMEA
- Latina America
- Middle East and Africa
CHAPTER: 1 INTRODUCTION
1.1 Report Description
1.2 Key Market Benefits
1.3 Key Market Segments
1.4 Research Methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER: 2 EXECUTIVE SUMMARY
2.1 CXO Perspective
2.2 Market Beyond What to Expect by 2025 ($million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER: 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Key Findings
3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies
3.3 Government Regulation
3.4 Reimbursement Scenario
3.5 Porter's Five Force Analysis
3.5.1 Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
3.5.2 Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
3.5.3 High capital investment and patent provision lowers the threats from new entrants
3.5.4 Difficulty to imitate the original biologics lowers the threat of substitutes
3.5.5 Industry rivalry is low to moderate due to presence of few competitors
3.6 Value Chain Analysis
3.7 Market Share Analysis, 2014
3.8 Market Dynamics
3.8.1 Drivers
3.8.1.1 Rising incidences of autoimmnue and respiratory conditions:
3.8.1.2 New Drugs in Pipeline
3.8.1.3 Increasing adoption rate of anti-inflammatory drugs
3.8.2 Restraints
3.8.2.1 Side effects of anti-inflammtory drugs
3.8.2.2 Patenet expiries
3.8.3 Opportunities
3.8.3.1 Developing biosimilars for the existing drugs
3.8.3.2 Tapping the emerging markets in developing regions
CHAPTER: 4 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY INDICATION
4.1 Market size and forecast by Indication
4.2.1 Market size and forecast by region
4.2.2 Rheumatoid Arthritis
4.2.3 Osteoarthritis
4.2.4 Ankylosing Spondylitis
4.2.5 Psoriatic Arthritis
4.2.6 Gout
4.3 Respiratory Diseases
4.3.1 Market size and forecast by region
4.3.2 Asthma
4.3.3 Chronic obstructive pulmonary disease (COPD)
4.4 Multiple Sclerosis
4.4.1 Market size and forecast by region
4.5 Psoriasis
4.5.1 Market size and forecast by region
4.6 Inflammatory Bowel Disease (IBD)
4.6.1 Market size and forecast by region
4.6.2 Crohn's Disease
4.6.3 Ulcerative Colitis
4.7 Other Inflammatory Diseases
4.7.1 Market size and forecast by region
CHAPTER: 5 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS
5.1 Anti-inflammatory Biologics
5.1.1 Key market trend
5.1.2 Market growth factors and opportunities
5.1.3 Market size and forecast by region
5.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.2.1 Key market trend
5.2.2 Market growth factors and opportunities
5.2.3 Market size and forecast by region
5.3 Corticosteroids
5.3.1 Key market trends
5.3.2 Market growth factors and opportunities
5.3.3 Market size and forecast by region
5.4 Other Anti-Inflammatory Drugs
CHAPTER: 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY
6.1 North America
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.1.4 United States
6.1.5 Canada
6.1.6 Mexico
6.2 Europe
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 United Kingdom
6.2.5 Germany
6.2.6 France
6.2.7 Rest of Europe
6.3 Asia Pacific
6.3.1 Key growth factors and opportunities
6.3.2 Market size and forecast
6.3.3 Japan
6.3.4 China
6.3.5 India
6.3.6 Rest of Asia Pacific
6.4 LAMEA
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Latin America
6.4.5 Middle East and Africa
CHAPTER: 7 COMPANY PROFILES
7.1 Pfizer Inc.
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Business performance
7.1.4 Strategic moves and developments
7.1.5 SWOT analysis of Pfizer, Inc.
7.2 AbbVie Inc.
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Business performance
7.2.4 Strategic Moves and Developments
7.2.5 SWOT analysis of AbbVie Inc.
7.3 Johnson & Johnson
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Business performance
7.3.4 Strategic moves and developments
7.3.5 SWOT analysis & strategic conclusions
7.4 GlaxoSmithKline plc
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Business performance
7.4.4 Strategic moves and developments
7.4.5 SWOT analysis & strategic conclusions
7.5 Merck & Co., Inc.
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Business performance
7.5.4 Strategic moves and developments
7.5.5 SWOT analysis and strategic conclusions
7.6 Novartis AG
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Business Performance
7.6.4 Strategic moves and developments
7.6.5 SWOT analysis and strategic conclusions
7.7 F. Hoffmann-La Roche AG
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Business performance
7.7.4 Strategic moves and developments
7.7.5 SWOT analysis and strategic conclusions
7.8 Eli Lily and Company
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Strategic moves and developments
7.8.5 SWOT analysis and strategic conclusions
7.9 AstraZeneca PLC.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Business performance
7.9.4 Strategic moves and developments
7.9.5 SWOT analysis and strategic conclusions
7.10 Amgen Inc.
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Business performance
7.10.4 Strategic moves and developments
7.10.5 SWOT analysis and strategic conclusions
1.1 Report Description
1.2 Key Market Benefits
1.3 Key Market Segments
1.4 Research Methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER: 2 EXECUTIVE SUMMARY
2.1 CXO Perspective
2.2 Market Beyond What to Expect by 2025 ($million)
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER: 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Key Findings
3.2.1 Top impacting factors
3.2.2 Top investment pockets
3.2.3 Top winning strategies
3.3 Government Regulation
3.4 Reimbursement Scenario
3.5 Porter's Five Force Analysis
3.5.1 Complex and highly differentiated nature of raw materials increases bargaining power of suppliers
3.5.2 Fewer manufacturers of anti-inflammatory drugs limits the bargaining power of buyers
3.5.3 High capital investment and patent provision lowers the threats from new entrants
3.5.4 Difficulty to imitate the original biologics lowers the threat of substitutes
3.5.5 Industry rivalry is low to moderate due to presence of few competitors
3.6 Value Chain Analysis
3.7 Market Share Analysis, 2014
3.8 Market Dynamics
3.8.1 Drivers
3.8.1.1 Rising incidences of autoimmnue and respiratory conditions:
3.8.1.2 New Drugs in Pipeline
3.8.1.3 Increasing adoption rate of anti-inflammatory drugs
3.8.2 Restraints
3.8.2.1 Side effects of anti-inflammtory drugs
3.8.2.2 Patenet expiries
3.8.3 Opportunities
3.8.3.1 Developing biosimilars for the existing drugs
3.8.3.2 Tapping the emerging markets in developing regions
CHAPTER: 4 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY INDICATION
4.1 Market size and forecast by Indication
4.2.1 Market size and forecast by region
4.2.2 Rheumatoid Arthritis
4.2.3 Osteoarthritis
4.2.4 Ankylosing Spondylitis
4.2.5 Psoriatic Arthritis
4.2.6 Gout
4.3 Respiratory Diseases
4.3.1 Market size and forecast by region
4.3.2 Asthma
4.3.3 Chronic obstructive pulmonary disease (COPD)
4.4 Multiple Sclerosis
4.4.1 Market size and forecast by region
4.5 Psoriasis
4.5.1 Market size and forecast by region
4.6 Inflammatory Bowel Disease (IBD)
4.6.1 Market size and forecast by region
4.6.2 Crohn's Disease
4.6.3 Ulcerative Colitis
4.7 Other Inflammatory Diseases
4.7.1 Market size and forecast by region
CHAPTER: 5 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS
5.1 Anti-inflammatory Biologics
5.1.1 Key market trend
5.1.2 Market growth factors and opportunities
5.1.3 Market size and forecast by region
5.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.2.1 Key market trend
5.2.2 Market growth factors and opportunities
5.2.3 Market size and forecast by region
5.3 Corticosteroids
5.3.1 Key market trends
5.3.2 Market growth factors and opportunities
5.3.3 Market size and forecast by region
5.4 Other Anti-Inflammatory Drugs
CHAPTER: 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY
6.1 North America
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.1.4 United States
6.1.5 Canada
6.1.6 Mexico
6.2 Europe
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 United Kingdom
6.2.5 Germany
6.2.6 France
6.2.7 Rest of Europe
6.3 Asia Pacific
6.3.1 Key growth factors and opportunities
6.3.2 Market size and forecast
6.3.3 Japan
6.3.4 China
6.3.5 India
6.3.6 Rest of Asia Pacific
6.4 LAMEA
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Latin America
6.4.5 Middle East and Africa
CHAPTER: 7 COMPANY PROFILES
7.1 Pfizer Inc.
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Business performance
7.1.4 Strategic moves and developments
7.1.5 SWOT analysis of Pfizer, Inc.
7.2 AbbVie Inc.
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Business performance
7.2.4 Strategic Moves and Developments
7.2.5 SWOT analysis of AbbVie Inc.
7.3 Johnson & Johnson
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Business performance
7.3.4 Strategic moves and developments
7.3.5 SWOT analysis & strategic conclusions
7.4 GlaxoSmithKline plc
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Business performance
7.4.4 Strategic moves and developments
7.4.5 SWOT analysis & strategic conclusions
7.5 Merck & Co., Inc.
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Business performance
7.5.4 Strategic moves and developments
7.5.5 SWOT analysis and strategic conclusions
7.6 Novartis AG
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Business Performance
7.6.4 Strategic moves and developments
7.6.5 SWOT analysis and strategic conclusions
7.7 F. Hoffmann-La Roche AG
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Business performance
7.7.4 Strategic moves and developments
7.7.5 SWOT analysis and strategic conclusions
7.8 Eli Lily and Company
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Business performance
7.8.4 Strategic moves and developments
7.8.5 SWOT analysis and strategic conclusions
7.9 AstraZeneca PLC.
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Business performance
7.9.4 Strategic moves and developments
7.9.5 SWOT analysis and strategic conclusions
7.10 Amgen Inc.
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Business performance
7.10.4 Strategic moves and developments
7.10.5 SWOT analysis and strategic conclusions
LIST OF TABLES
TABLE 1 GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET MODERATE GROWTH SCENARIO, REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
TABLE 2 GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET RAPID GROWTH SCENARIO REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
TABLE 3 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET DIMINISHING GROWTH SCENARIO REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
TABLE 4 PATENT EXPIRY OF MAJOR BRANDS
TABLE 5 PROJECTED INCIDENCE OF ARTHRITIS IN U.S
TABLE 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2014-2020, ($MILLION)
TABLE 7 GLOBAL ARTHRITIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 8 GLOBAL RESPIRATORY DISEASES ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 9 GLOBAL MULTIPLE SCLEROSIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 10 GLOBAL PSORIASIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 11 GLOBAL INFLAMMTORY BOWEL DISEASE ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 12 GLOBAL OTHER INFLAMMTORY DISEASES ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 13 GLOBAL ANTI INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020, $MILLION
TABLE 14 GLOBAL TOP SELLING BIOLOGIC ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 15 GLOBAL ANTI-INFLAMMATORY BIOLOGICS THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 16 GLOBAL NSAIDS THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 17 GLOBAL TOP SELLING CORTICOSTEROIDS ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 18 GLOBAL CORTICOSTEROIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 19 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 20 NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 21 NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 22 EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 23 EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 24 ASIA PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 25 ASIA PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 26 LAMEA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 27 LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 28 PFIZER INC SNAPSHOT
TABLE 29 ABBVIE INC. SNAPSHOT
TABLE 30 JOHNSON & JOHNSON SNAPSHOT
TABLE 31 GLAXOSMITHKLINE SNAPSHOT
TABLE 32 MERCK & CO SNAPSHOT
TABLE 33 NOVARTIS AG SNAPSHOT
TABLE 34 F. HOFFMANN-LA ROCHE AG SNAPSHOT
TABLE 35 ELI LILLY SNAPSHOT
TABLE 36 ASTRAZENECA SNAPSHOT
TABLE 37 AMGEN INC SNAPSHOT
TABLE 1 GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET MODERATE GROWTH SCENARIO, REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
TABLE 2 GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET RAPID GROWTH SCENARIO REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
TABLE 3 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET DIMINISHING GROWTH SCENARIO REVENUE BY GEOGRAPHY, 2020-2025 ($ MILLION)
TABLE 4 PATENT EXPIRY OF MAJOR BRANDS
TABLE 5 PROJECTED INCIDENCE OF ARTHRITIS IN U.S
TABLE 6 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2014-2020, ($MILLION)
TABLE 7 GLOBAL ARTHRITIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 8 GLOBAL RESPIRATORY DISEASES ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 9 GLOBAL MULTIPLE SCLEROSIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 10 GLOBAL PSORIASIS ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 11 GLOBAL INFLAMMTORY BOWEL DISEASE ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 12 GLOBAL OTHER INFLAMMTORY DISEASES ANTI INFLAMMTORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, $MILLION
TABLE 13 GLOBAL ANTI INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020, $MILLION
TABLE 14 GLOBAL TOP SELLING BIOLOGIC ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 15 GLOBAL ANTI-INFLAMMATORY BIOLOGICS THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 16 GLOBAL NSAIDS THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 17 GLOBAL TOP SELLING CORTICOSTEROIDS ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 18 GLOBAL CORTICOSTEROIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020, ($MILLION)
TABLE 19 GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET BY GEOGRAPHY, 2014-2020 ($MILLION)
TABLE 20 NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 21 NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 22 EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 23 EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 24 ASIA PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 25 ASIA PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 26 LAMEA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 27 LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 28 PFIZER INC SNAPSHOT
TABLE 29 ABBVIE INC. SNAPSHOT
TABLE 30 JOHNSON & JOHNSON SNAPSHOT
TABLE 31 GLAXOSMITHKLINE SNAPSHOT
TABLE 32 MERCK & CO SNAPSHOT
TABLE 33 NOVARTIS AG SNAPSHOT
TABLE 34 F. HOFFMANN-LA ROCHE AG SNAPSHOT
TABLE 35 ELI LILLY SNAPSHOT
TABLE 36 ASTRAZENECA SNAPSHOT
TABLE 37 AMGEN INC SNAPSHOT
LIST OF FIGURES
FIG. 1 TOP IMPACTING FACTORS, MODERATE GROWTH SCENARIO (2020-2025)
FIG. 2 TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2020-2025)
FIG. 3 TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2020-2025)
FIG. 4 TYPES OF ANTI-INFALMMATORY THERAPEUTICS:
FIG. 5 TOP FACTORS IMPACTING ON GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014-2020)
FIG. 6 TOP INVESTMENT POCKETS OF ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014)
FIG. 7 TOP WINNING STRATEGIES IN ANTI-INFLAMMATORY THERAPEUTICSMARKET
FIG. 8 PHARMACEUTICALS REGULATORY PATHWAY (U.S.)
FIG. 9 PORTER'S FIVE FORCES ANALYSIS
FIG. 10 VALUE CHAIN OF GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET
FIG. 11 MARKET SHARE ANALYSIS, 2014
FIG. 12 FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 13 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 14 FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 15 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 16 ABBVIE, INC. FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 17 FINANCIAL REVENUES OF HUMIRA ($MILLION)
FIG. 18 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 19 PHARMACEUTICALS SALES BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 21 GLAXOSMITHKLINE'S FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 22 FINANCIAL REVENUES BY THERAPY AREA
FIG. 23 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 24 FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 25 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 26 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 27 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 28 FINANCIAL REVENUES BY SEGMENT (2014)
FIG. 29 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 30 FIANANCIAL REVENUES BY THERAPEUTIC SEGMENTS (2014)
FIG. 31 FINANCIAL REVENUES OF PHARMACEUTICALS BY REGION
FIG. 32 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 33 FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 34 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 35 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 36 FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 37 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 38 FINANCIAL REVENUES BY PRODUCT (2014)
FIG. 39 FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 40 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 1 TOP IMPACTING FACTORS, MODERATE GROWTH SCENARIO (2020-2025)
FIG. 2 TOP IMPACTING FACTORS, RAPID GROWTH SCENARIO (2020-2025)
FIG. 3 TOP IMPACTING FACTORS, DIMINISHING GROWTH SCENARIO (2020-2025)
FIG. 4 TYPES OF ANTI-INFALMMATORY THERAPEUTICS:
FIG. 5 TOP FACTORS IMPACTING ON GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014-2020)
FIG. 6 TOP INVESTMENT POCKETS OF ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014)
FIG. 7 TOP WINNING STRATEGIES IN ANTI-INFLAMMATORY THERAPEUTICSMARKET
FIG. 8 PHARMACEUTICALS REGULATORY PATHWAY (U.S.)
FIG. 9 PORTER'S FIVE FORCES ANALYSIS
FIG. 10 VALUE CHAIN OF GLOBAL ANTI-INFLAMMTORY THERAPEUTICS MARKET
FIG. 11 MARKET SHARE ANALYSIS, 2014
FIG. 12 FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 13 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 14 FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 15 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 16 ABBVIE, INC. FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 17 FINANCIAL REVENUES OF HUMIRA ($MILLION)
FIG. 18 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 19 PHARMACEUTICALS SALES BY GEOGRAPHY (2014)
FIG. 20 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 21 GLAXOSMITHKLINE'S FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 22 FINANCIAL REVENUES BY THERAPY AREA
FIG. 23 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 24 FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 25 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 26 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 27 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 28 FINANCIAL REVENUES BY SEGMENT (2014)
FIG. 29 SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 30 FIANANCIAL REVENUES BY THERAPEUTIC SEGMENTS (2014)
FIG. 31 FINANCIAL REVENUES OF PHARMACEUTICALS BY REGION
FIG. 32 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 33 FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 34 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 35 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 36 FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 37 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 38 FINANCIAL REVENUES BY PRODUCT (2014)
FIG. 39 FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 40 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
